Phesgo and Tecentriq Performance and Approvals

Q1 2023: Portfolio diversification ongoing CHFM 16'445 +146 -3% at CER +48 -1'626 +1'262 -333 -620 15'322 Q1 2022 Dia base business Dia COVID-19 sales Pharma Ronapreve underlying sales business AHR erosion1 Fx Q1 2023 Values in reported CHFm, variances in CERm; 1AHR: Avastin, Herceptin, Rituxan/MabThera sales erosion Diversification of Roche portfolio Q1 2018 CHF 13.6bn Q1 2023 CHF 15.3bn Roche Diagnostics Other pharma Ophthalmology Neuroscience Hemophilia A Infectious diseases Oncology Immunology AHR 8

View entire presentation